Rishi Singh, MD
Ophthalmology · Boston, MANPI 1750447660
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 18.2%. Reporting peaked in 2023 at $455,984 and has fallen 55.9% since, to $201,187 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,020 payments — averaging $1656.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$307K
- Regeneron Healthcare Solutions, Inc.$247K
- Genentech USA, Inc.$147K
- Alcon$109K
- Genentech, Inc.$101K
- Novartis$92K
- plus $687K from 36 others
Across 188 payments — averaging $5243.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$303K
- Genentech, Inc.$179K
- Regeneron$112K
- F. Hoffmann-la Roche AG$109K
- Ocular Therapeutix, Inc.$78K
- Carl Zeiss Meditec, Inc.$68K
- plus $137K from 5 others
What the payments were for
- Consulting fees$873,27652%
- Speaking & faculty fees$668,23040%
- Travel & lodging$120,0757%
- Food & beverage$27,8142%
- Gifts$2800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$197,997
- Syfovre$179,436
- VABYSMO$176,455
- BEOVU$85,968
- EYLEA HD$84,627
- Constellation$80,859
- Izervay$54,831
- OZURDEX$46,541
- YUTIQ$45,884
- EYP-1901$43,262
- Lucentis$43,129
- CIRRUS HD-OCT$42,550
- Cimerli$38,465
- NGENUITY$28,690
- Iluvien$24,004
- CLARUS$23,780
- Alcon Greishaber Finesse$20,089
- OPMI Lumera 700$15,807
- FORUM$14,020
- PURIFIED CORTROPHIN GEL$13,520
How this compares
$1,689,674 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Boston
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
- Michael RaizmanBoston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.